Headlines about Corcept Therapeutics (NASDAQ:CORT) have trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Corcept Therapeutics earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 30 out of 100, meaning that recent media coverage is unlikely to have an effect on the company’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
- Stock Chatter: A Look into Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares – Stock Press Daily (stockpressdaily.com)
- Is It Too Late to Get In on This Millionaire-Maker Stock? (fool.com)
- David L. Mahoney Sells 6,994 Shares of Corcept Therapeutics Incorporated (CORT) Stock (americanbankingnews.com)
- Corcept Therapeutics Incorporated (NASDAQ:CORT) Director David L. Mahoney Sells 6,510 Shares (americanbankingnews.com)
- Corcept Therapeutics Focuses on Korlym’s Label Expansion (mrtopstep.com)
Shares of Corcept Therapeutics (NASDAQ CORT) opened at 12.16 on Tuesday. Corcept Therapeutics has a 1-year low of $5.24 and a 1-year high of $12.74. The company’s 50-day moving average is $11.49 and its 200 day moving average is $9.64. The company has a market cap of $1.38 billion, a price-to-earnings ratio of 111.56 and a beta of 2.05.
Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Monday, May 1st. The biotechnology company reported $0.04 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.01. The company had revenue of $27.60 million for the quarter, compared to the consensus estimate of $25.53 million. Corcept Therapeutics had a net margin of 13.51% and a return on equity of 33.97%. The business’s quarterly revenue was up 71.9% compared to the same quarter last year. Equities analysts anticipate that Corcept Therapeutics will post $0.26 EPS for the current year.
CORT has been the topic of a number of research reports. TheStreet lowered shares of Corcept Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, May 1st. Zacks Investment Research lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 8th. Piper Jaffray Companies set a $18.00 target price on shares of Corcept Therapeutics and gave the company a “buy” rating in a research note on Monday, May 15th. Finally, BidaskClub lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, June 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $11.75.
In other Corcept Therapeutics news, Director David L. Mahoney sold 6,994 shares of the firm’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $12.50, for a total transaction of $87,425.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David L. Mahoney sold 6,510 shares of the firm’s stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $12.50, for a total transaction of $81,375.00. The disclosure for this sale can be found here. Company insiders own 19.20% of the company’s stock.
About Corcept Therapeutics
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).
Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.